What question did this study set out to answer?

Assess the effects of renal denervation on liver health in patients with metabolic syndrome and hypertension.

February 26, 2026Open Access

Renal Denervation Improves Hepatic Steatosis in Hypertensive Patients With Metabolic Syndrome

Q: What does this research mean for the field?

Renal denervation significantly reduces the Hepatic Steatosis Index (HSI) and Fatty Liver Index (FLI) in hypertensive patients with metabolic syndrome. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Key Result

Renal denervation significantly reduced Hepatic Steatosis Index (HSI) and Fatty Liver Index (FLI) in hypertensive patients with metabolic syndrome.

Key Points

Assess the effects of renal denervation on liver health in patients with metabolic syndrome and hypertension.
Conducted intervention study in hypertensive patients with metabolic syndrome
Administered renal denervation (RDN) procedure
Evaluated hepatic steatosis using Hepatic Steatosis Index (HSI) and Fatty Liver Index (FLI)
Significant reduction in Hepatic Steatosis Index (HSI) levels post-RDN
Notable decrease in Fatty Liver Index (FLI) scores
Indicates potential benefits for managing liver health in metabolic disorders

Structured PICO

Does renal denervation improve hepatic steatosis in hypertensive patients with metabolic syndrome?

Population

Patients with uncontrolled hypertension and cardiometabolic comorbidities (metabolic syndrome)

Intervention

Renal denervation (RDN)

Outcome

Hepatic Steatosis Index (HSI) and Fatty Liver Index (FLI)surrogate

Renal denervation significantly reduces surrogate markers of hepatic steatosis in patients with uncontrolled hypertension and metabolic syndrome.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

RDN significantly reduced HSI and FLI in patients with uncontrolled hypertension and cardiometabolic comorbidities, suggesting a potential role of sympathetic modulation in metabolic disorders.